Home › Companies › BCAX

Bicara Therapeutics

BCAX Lead: Phase 3 1 Biotech Distilled article ↓

Oncology Protein

Most recent annual filing: 2026-03-30

Pipeline (4 active programs)

ficerafusp alfa

BCA101

Protein Target: EGFR, TGF-β

Head and Neck Squamous Cell Carcinoma Phase 3
Colorectal Cancer Phase 1
Cutaneous Squamous Cell Carcinoma Phase 1
Anal Squamous Cell Carcinoma Phase 1

Biotech Distilled coverage (1)

2026-05-30 Bicara Therapeutics (BCAX) — Scientific Deep Dive for Ficerafusp Alfa and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.